Business Wire

CA-EXPERIAN

22.5.2024 12:01:30 CEST | Business Wire | Press release

Share
Enhanced Experian Ascend Technology Platform™ Transforms Software for Credit, Fraud and Analytics

As companies around the globe grapple with an accelerated pace of change and seek ways to optimize their businesses, Experian® is ushering in a new era of simplification, scalability and automation through the debut of new enhancements to its cloud-based Experian Ascend Technology Platform™. Now, Experian’s award-winning platform brings together software tools for analytics, credit decisioning and fraud into a single interface — simplifying the deployment of analytical models and enabling businesses to optimize their practices more frequently, achieving greater efficacy with lower investment of time and money.

Experian’s enhancements were unveiled to more than 500 business leaders during its annual Vision conference in Scottsdale, Ariz., and represent a significant evolution in streamlining business-to-business software solutions.

Why it matters:

  • The world’s top technology companies have set the standard for seamless user experiences and integrations between software components through single sign-on, data portability, and sophisticated no-code or low-code functionality.
  • Historically, this type of synchronized experience has been unattainable to many businesses, especially those in the financial services sector.
  • Typically, organizations buy software solutions from many different vendors, leverage a variety of tools and applications across different cloud environments, and go through rigorous and time-consuming processes to stitch everything together.
  • This fragmented approach stretches timelines unnecessarily, raises security concerns and creates operational challenges. It also increases costs and the likelihood of errors or downtime because such setups are only as strong as their weakest link, perpetually causing issues when any single component fails.

“IT services companies are increasingly delivering their software portfolios as pre-integrated platforms that deliver scale, efficiency, productivity,” said Raymond Pucci, IDC Research Director, Worldwide Lending Digital Strategies. “For lenders, enterprise architectures like Experian's Ascend Technology Platform can enable faster credit-decisioning velocity, higher loan quality, and stronger risk management, expanding customer relationships and increasing business growth.”

The updates to Experian’s platform represent a notable milestone — fueled by Experian’s significant investments in innovation over the last eight years as part of its modern cloud transformation.

“Our mission is to develop world-class software and support organizations around the world on their journeys toward more sophisticated fraud prevention, marketing and credit strategies,” said Alex Lintner, CEO, Experian Software Solutions. “The evolution of our platform reaffirms our commitment to drive innovation and empower businesses to thrive. Its capabilities are unmatched and represent a significant leap forward in lending technology, democratizing access to data in compliant ways while enabling lenders of all sizes to seamlessly validate their customers’ identities with confidence, help expand fair access to credit and offer awesome user and customer experiences.”

Experian’s global scalability

Experian’s platform is available now in regions including North America, Brazil and the United Kingdom. The enhanced platform is being leveraged by more than 1,500 clients globally, processing 14 million credit reports daily and billions of credit and fraud transactions per year. In North America alone, over 8,000 registered users from 80 clients access over 12 petabytes of data weekly for analytical purposes.

A simplified and scalable approach

The enhanced Experian Ascend Technology Platform now dramatically reduces time to install and offers streamlined access to many of Experian's award-winning integrated solutions and tools through a single sign-on and managed via a user-friendly dashboard.

The platform leverages generative AI and makes it easy for clients from organizations of varying sizes and experience levels to pivot between applications, automate processes, modernize operations and drive efficiency. In addition, existing clients using Experian solutions today can now easily add new capabilities through the platform to enhance business outcomes.

For example, Lendr, a specialized fintech offering contemporary financing solutions for small businesses, is harnessing the power of the platform to enhance competitiveness and informed decision-making.

“Utilizing Experian Ascend Technology Platform has significantly bolstered our agility and competitive edge, empowering us to execute more informed, data-driven credit decisions while substantially reducing our time to market,” remarked Daniel DeMeo, CEO of Lendr. “Experian’s platform helps deliver the scalability we need to be nimble, compete effectively and mitigate losses — ultimately helping us double our business over the past year.”

Additional key features and benefits of the platform include:

  • Analytics and model development: Clients can easily access and harness Experian's proprietary credit and expanded data attributes with powerful analytical tools for insights and explainable model creation.
  • Rapid model deployment: Build, test and deploy models from a single interface in days rather than months, streamlining processes and enhancing customer experiences.
  • Automated decisioning and risk mitigation: Enables secure, automated decisions and risk mitigation across the customer lifecycle, ensuring efficient operations and improved outcomes.
  • Fraud and identity verification: Experian’s platform stops fraudsters faster and streamlines consumer experiences via a suite of software services powered by advanced AI analytics and comprehensive data assets across digital identity, device intelligence, behavioral analytics and credit insights. It delivers unrivaled identity verification and fraud risk detection to enable businesses to grow revenue through seamless consumer experiences and reduce fraud loss exposure.
  • Expertise through managed services: While the platform offers automation and low-code functionality, clients can also access Experian’s expertise and top talent through managed services, democratizing advanced analytics techniques for lenders regardless of their resources or analytics experience.
  • Continuous monitoring and feedback: Receive continuous monitoring and feedback to adapt strategies in real time and stay ahead of evolving challenges.
  • Unparalleled security: The platform is fortified with encryption, robust access controls and proactive threat detection — while maintaining high availability and Enterprise-grade performance.

For more information about Experian’s platform, please visit https://www.experian.com/business/products/ascend.

About Experian

Experian is a global data and technology company, powering opportunities for people and businesses around the world. We help to redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain deeper insights into the automotive market, all using our unique combination of data, analytics and software. We also assist millions of people to realize their financial goals and help them to save time and money.

We operate across a range of markets, from financial services to healthcare, automotive, agrifinance, insurance, and many more industry segments.

We invest in talented people and new advanced technologies to unlock the power of data and innovate. As a FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have a team of 22,500 people across 32 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at experianplc.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522675866/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye